Rapport Therapeutics, Inc. Common Stock
General ticker "RAPP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $843.5M (TTM average)
Rapport Therapeutics, Inc. Common Stock follows the US Stock Market performance with the rate: 55.2%.
Estimated limits based on current volatility of 3.5%: low 36.97$, high 39.63$
Factors to consider:
- Total employees count: 69 as of 2024
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [17.32$, 40.89$]
- 2026-12-31 to 2027-12-31 estimated range: [11.32$, 28.62$]
Short-term RAPP quotes
Long-term RAPP plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $36.18MM | $83.06MM | $125.10MM |
| Operating Income | $-36.18MM | $-83.06MM | $-125.10MM |
| Non-Operating Income | $1.40MM | $5.27MM | $12.55MM |
| R&D Expense | $28.00MM | $60.94MM | $94.79MM |
| Income(Loss) | $-34.78MM | $-77.78MM | $-112.55MM |
| Taxes | $0.01MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-34.79MM | $-78.31MM | $-112.55MM |
| Stockholders Equity | $-25.63MM | $305.43MM | $484.65MM |
| Assets | $155.42MM | $314.93MM | $512.43MM |
| Operating Cash Flow | $-27.18MM | $-64.83MM | $-87.47MM |
| Capital expenditure | $1.64MM | $2.40MM | $0.62MM |
| Investing Cash Flow | $-78.86MM | $-170.14MM | $-187.47MM |
| Financing Cash Flow | $145.14MM | $221.62MM | $270.79MM |
| Earnings Per Share** | $-1.92 | $-3.78 | $-2.40 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.